• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Biologically Active
  • Hot Products
  • Plant Catalog
  • Products
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Ginsenoside Rg3

    Catalog No. CFN99969
    CAS No. 14197-60-5
    Molecular Weight: 785.02
    Molecular Formula C42H72O13
    DBs [PubChem]:254741245
    [ChEMBL]:67991
    [PCIDB]:30400

    Standard InChI:

    InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1

    Biological Activity

    Ginsenoside-Rg3, possess an ability to inhibit the lung metastasis of tumor cells, and the mechanism of their antimetastatic effect is related to inhibition of the adhesion and invasion of tumor cells, and also to anti-angiogenesis activity.[1]
    Ginsenoside-Rg3 (2.5 or 5.0 mg/kg body weight,s.c. injections) inhibits cancer metastasis through activities that do not affect the growth or vascularity of intestinal cancers.[2]
    Ginsenoside Rg3 has anti-tumor property through its angiosuppressive activity, is a ginsenoside monomer with high anti-cancer activity.[3,4]
    Ginsenoside-Rg3 has new pharmacological activity against testosterone-induced prostate overgrowth,downregulates AR by facilitating the degradation of AR protein, could be potential therapeutic regimens for treating BPH.[5]
    Ginsenoside-Rg3 is a novel drug, capable of inhibiting the early of scarring (HS) and later HS. GS-Rg3/electrospun is a very promising new treatment for early and long-term treatment of HS.[6]

    Product

    Official website: Ginsenoside Rg3
    Japanese website: Ginsenoside Rg3
    Chinese website: Ginsenoside Rg3

    References

    [1] Mochizuki M, Yoo Y C, Matsuzawa K, et al. Biol Pharm Bull, 1995, 18(9):1197-202.
    [2] Iishi H, Tatsuta M, Baba M, et al. Clin Exp Metastas , 1997, 15(6):603-11.
    [3] Yue P Y K, Wong D Y L, Wu P K, et al. Biochem Pharmcol, 2006, 72(4):437-45.
    [4] Xue-Long L I, Yao-Yao F U, Sun S Y, et al. Journal of Dalian Polytechnic University, 2010,29(6):396-8.
    [5] Bae J S, Park H S, Park J W, et al. J Nat Med, 2012, 66(3):476-85.
    [6] Cheng L, Sun X, Hu C, et al. Acta Biomater, 2013, 9(12):9461-73.
    [7] Zhao Q, Zheng X, Jiang J, et al. J Chromatogr B , 2010, 878(24): 2266-73.

    Product Use Citation